Phase I, Open Label, Randomized, Drug-Drug Interaction Study in Healthy Subjects to Investigate the Effects of Co-Administered Atazanavir/Ritonavir (300mg/100mg) or Atazanavir 400mg Administered Once Daily on the Steady-State Plasma Pharmacokinetics of GSK1349572 30mg Administered Once Daily.

Trial Profile

Phase I, Open Label, Randomized, Drug-Drug Interaction Study in Healthy Subjects to Investigate the Effects of Co-Administered Atazanavir/Ritonavir (300mg/100mg) or Atazanavir 400mg Administered Once Daily on the Steady-State Plasma Pharmacokinetics of GSK1349572 30mg Administered Once Daily.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2010

At a glance

  • Drugs Atazanavir; Dolutegravir; Ritonavir
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 19 Feb 2010 Results presented at the 17th Conference on Retroviruses and Opportunistic Infections (CROI-2010).
    • 23 Jun 2009 Actual end date (1 Jun 2009) added as reported by ClinicalTrials.gov.
    • 23 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top